March 31

Exscientia Business Update for First Quarter 2023

Retrieved on: 
Wednesday, May 24, 2023
Technology, Research, Health Technology, Biotechnology, Health, Pharmaceutical, Science, Artificial Intelligence, Oncology, Federal Reserve Bank, LSD1, Society, International, RCC, Sumitomo Pharma, IGNITE, Clinical trial, Bone marrow, SLAS, G&A, NSCLC, Lung cancer, USD, ID, EDT, Drug design, MALT1, Data as a service, Patient, Blood, Drug discovery, Exhibition, Depreciation, Growth, GBP, Laboratory automation, Conference, March 31, Automation, BST, Pharmaceutical industry, Cryptocurrency, Video game, Bank

Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the first quarter 2023, are summarised below.

Key Points: 
  • Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the first quarter 2023, are summarised below.
  • Revenue: Revenue for the first quarter 2023 was $7.1 million, compared to $8.6 million for the three months ended March 31, 2022.
  • For the first quarter 2023, G&A expenses increased by $3.8 million compared to the first quarter 2022, primarily associated with an increase in personnel costs associated with growth in headcount.
  • Cash inflows: For the first quarter 2023, Exscientia received $0.5 million in cash inflows from its collaborations as compared to $6.3 million during the first quarter 2022.

First Financial Corporation Reports First Quarter Results

Retrieved on: 
Tuesday, April 25, 2023
Book value, AOCI, FDIC, Commercial property, First Financial Bank, Sale, Non, Development, Investment, Management, Growth, Environment, March 31, Bank, Life insurance, Cryptocurrency, Real estate, Video game

TERRE HAUTE, Ind., April 25, 2023 (GLOBE NEWSWIRE) -- First Financial Corporation (NASDAQ:THFF) today announced results for the first quarter of 2023.

Key Points: 
  • TERRE HAUTE, Ind., April 25, 2023 (GLOBE NEWSWIRE) -- First Financial Corporation (NASDAQ:THFF) today announced results for the first quarter of 2023.
  • On a linked quarter basis, total loans increased $12.6 million or 0.41% from $3.07 billion as of December 31, 2022.
  • “We are pleased with our first quarter results, as we experienced another quarter of loan growth and expansion of our net interest margin, contributing to our eighth consecutive quarter of net interest income growth.
  • Pretax income for the first quarter 2022 was significantly higher than pretax income for first quarter 2023.

Cipher Pharmaceuticals Reports Strong First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 12, 2022
CPH, Telephone, Company, Eflornithine, Conversation, Mission statement, EBITDA, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Depreciation, Webcast, Sun Pharma, Moberg, Goal, Insurance, SEDAR, Tax, Coronavirus, Risk, March 31, Privacy, COVID-19, Marketing, Adjustment, TSX, Tirofiban, FDA, Hope, Industry, Sun, Substance-related disorder, Partnership, Intellectual property, Compliance, Hospital, Management, Financial statement, Onychomycosis, IFRS, Adoption, Acquisition, Growth, Interim, Degenerative disease, Weapon, Online gambling, Pharmaceutical industry, Fine chemical, Renewable energy, Mobile phone, Bookkeeping, Isotretinoin, MISSISSAUGA, IQVIA, Isotretinoin

Our strong results have been driven by our reduced cost structure in addition to improved distribution and supply agreements."

Key Points: 
  • Our strong results have been driven by our reduced cost structure in addition to improved distribution and supply agreements."
  • During the first quarter, Cipher announced an extension of the distribution and supply agreement with Sun Pharmaceutical Industries ("Sun Pharma") through December 31, 2026.
  • This extension will provide Cipher with an additional four years of visibility into stable revenue and cashflow on the isotretinoin portfolio.
  • Cipher will hold a conference call onMay 13, 2022, at8:30 a.m. (ET)to discuss its financial results and other corporate developments.